Trimedyne to manufacture Lumenis' laser fiber for prostate surgery

By Elaine Rigoli

Tampa, Fla., May 19 - Trimedyne, Inc. reached an agreement with Lumenis, Ltd. under which Trimedyne will manufacture the DuraMax side-firing laser fiber exclusively for Lumenis.

The DuraMax Fiber will be marketed by Boston Scientific Corp., under the Boston Scientific label in the United States.

The new device will be used in conjunction with Lumenis' VersaPulse PowerSuite holmium laser for holmium laser ablation of the prostate, known as HoLAP.

HoLAP is a minimally invasive technique for the treatment of benign prostatic hyperplasia, or BPH. Sometimes referred to as enlarged prostate, BPH is a condition affecting an estimated 50% of men over age 50 and up to 90% of men over 80 years of age.

With HoLAP, prostate tissue is vaporized with holmium laser energy, according to a news release.

This virtually bloodless procedure provides almost immediate symptom relief with fewer complications than typical procedures, the release said.

"Our new, patented Fiber is exciting because it's designed to vaporize soft tissue faster and last longer than other fibers on the market today," said Glenn D. Yeik, Trimedyne president, in a statement.

"I'm very pleased to have well-respected industry leaders like Boston Scientific and Lumenis promote our new Fiber," he added.

Lumenis will market the DuraMax Fiber under its own label through its sales and distributor organizations in countries other than the United States. Lumenis and Boston Scientific expect the marketing of the DuraMax Fiber will begin in the United States and elsewhere throughout the world in the last quarter of 2006.

Boston Scientific develops medical devices and is based in Natick, Mass.

New York-based Lumenis develops laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications.

Trimedyne, based in Irvine, Calif., manufactures lasers and proprietary fiberoptic devices for minimally invasive surgical procedures.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.